Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer

This study is testing whether combining weekly paclitaxel or nab-paclitaxel (chemotherapy), pembrolizumab (an immunotherapy drug), and mirabegron (a drug used for overactive bladder, which also activates immune-boosting fat cells) can treat recurrent ovarian, fallopian tube, or peritoneal cancer. **You may be eligible if...** - You have confirmed epithelial ovarian, fallopian tube, or primary peritoneal cancer that has come back after prior treatment - You previously received at least one platinum-based chemotherapy regimen - You are in good overall physical condition (ECOG 0–1) **You may NOT be eligible if...** - You have autoimmune disease that requires systemic treatment - You have received prior pembrolizumab or similar checkpoint inhibitor drugs and experienced severe side effects - You have significant heart problems or uncontrolled infections Talk to your doctor to see if this trial is right for you.